| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 01/28/2010 | US20100022548 Use of n-heterocyclylmethylbenzamides in therapeutics |
| 01/28/2010 | US20100022540 Triazole derivatives ii |
| 01/28/2010 | US20100022536 Inhibitors of Cytosolic Phospholipase A2 |
| 01/28/2010 | US20100022531 Novel compounds as p2x7 modulators and uses thereof |
| 01/28/2010 | US20100022521 Compounds |
| 01/28/2010 | US20100022519 Heterocyclic-substituted piperidine compounds and the uses thereof |
| 01/28/2010 | US20100022514 Heterocycle Compounds and Methods of Use Thereof |
| 01/28/2010 | US20100022511 Stabilized Atypical Antipsychotic Formulation |
| 01/28/2010 | US20100022510 Crystalline Forms |
| 01/28/2010 | US20100022507 Aminopyrimidines useful as inhibitors of protein kinases |
| 01/28/2010 | US20100022502 Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases |
| 01/28/2010 | US20100022500 Macrocyclic Lactams and Pharmaceutical Use Thereof |
| 01/28/2010 | US20100022496 Galenical form for the administration of active ingredients by transmucous means |
| 01/28/2010 | US20100022486 Compounds |
| 01/28/2010 | US20100022478 Chiral compounds substituted with phosphonate acid ester functions or phosphonic acid functions |
| 01/28/2010 | US20100022459 Peptides directed for diagnosis and treatment of amyloid-associated diseases |
| 01/28/2010 | US20100022453 NoGo Receptor 1 and Fibroblast Growth Factor Interactions |
| 01/28/2010 | US20100022444 Combination therapy for modulation of activity and development of cells and tissues |
| 01/28/2010 | US20100021570 Smoking Cessation Treatment By Reducing Nicotine Cravings, Apetite Suppression, And Altering The Perceived Taste Of Tobacco Smoke |
| 01/28/2010 | US20100021567 Peganine Isolated from Anisotes Trisulcus L. as a Smoking Deterrent and Anorxigenic Agent |
| 01/28/2010 | US20100021555 Compositions containing high omega-3 and low saturated fatty acid levels |
| 01/28/2010 | US20100021543 Peroral solid pain killer preparation |
| 01/28/2010 | US20100021539 Modified Release 1-[(3-Hydroxy-Adamant-1-Ylamino)-Acetyl]-Pyrrolidine-2(S)-Carbonitrile Formulation |
| 01/28/2010 | US20100021482 Novel death associated proteins, and thap1 and par4 pathways in apoptosis control |
| 01/28/2010 | US20100021478 Diagnostic antibody assay |
| 01/28/2010 | US20100021469 Functional role of adrenomedullin (am) and the gene related product (pamp) in human pathology and physiology |
| 01/28/2010 | US20100021467 Method of detecting a cancer cell by aberrant expression of a human k+ ion channel |
| 01/28/2010 | US20100021451 Uses and compositions for treatment of ankylosing spondylitis |
| 01/28/2010 | US20100021437 Neural stem cells derived from induced pluripotent stem cells |
| 01/28/2010 | US20100021432 Sensitization of Chemotherapeutic Agent Resistant Neoplastic Cells with a Virus |
| 01/28/2010 | US20100021429 Cladribine regimen for treating multiple sclerosis |
| 01/28/2010 | US20100021422 Methods and compositions for delivery of exogenous factors to nervous system sites |
| 01/28/2010 | US20100021388 Benzothiazole derivative compounds, compositions and uses |
| 01/28/2010 | DE10297018B4 Depotmikrokügelchen für die Injektion von Huperzin-A-Verbindungen Depot microspheres for injection of Huperzine A compounds |
| 01/28/2010 | CA2736842A1 Proteins for use in diagnosing and treating infection and disease |
| 01/28/2010 | CA2734991A1 Activation of histone deacetylase 1 (hdac1) protects against dna damage and increases neuronal survival |
| 01/28/2010 | CA2732016A1 Tissue kallikrein for the treatment of parkinson's disease |
| 01/28/2010 | CA2731849A1 Treating various disorders with 7,8-dihydroxyflavone and derivatives thereof |
| 01/28/2010 | CA2731789A1 Alkyl thiazole carbamate derivatives, preparation thereof, and use thereof as faah enzyme inhibitors |
| 01/28/2010 | CA2731573A1 Therapeutic agent for migraine |
| 01/28/2010 | CA2731544A1 Aminophosphinic derivatives that can be used in the treatment of pain |
| 01/28/2010 | CA2731429A1 Large substituent, non-phenolic amine opioids |
| 01/28/2010 | CA2731295A1 Novel substituted sulfamide derivatives |
| 01/28/2010 | CA2731242A1 Compositions and methods related to sirt1 function |
| 01/28/2010 | CA2731190A1 Pyridinyl modulators of .gamma.-secretase |
| 01/28/2010 | CA2730288A1 Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof |
| 01/28/2010 | CA2729998A1 Inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| 01/28/2010 | CA2728629A1 Adamantyl diamide derivatives and uses of same |
| 01/28/2010 | CA2728480A1 4,5-dihydro-oxazol-2-yl derivatives |
| 01/27/2010 | EP2147922A1 Fused heterocyclic derivative, pharmaceutical composition comprising the derivative, and use of the composition for medical purposes |
| 01/27/2010 | EP2147915A1 New cycloalkylated benzothiadiazine derivatives, method of preparing same and pharmaceutical compositions containing them |
| 01/27/2010 | EP2147914A1 Aminodihydrothiazine derivatives substituted with cyclic groups |
| 01/27/2010 | EP2147683A1 Construct and method for the internalization of cargo molecules into a cell |
| 01/27/2010 | EP2147679A2 Compositions and methods for modulating blood-brain barrier transport |
| 01/27/2010 | EP2147673A1 Modulation of prostaglandin/cyclooxygenase metabolic pathways |
| 01/27/2010 | EP2146997A1 Substituted furo[2,3-b]pyridine derivatives as cannabinoid-1 receptor modulators |
| 01/27/2010 | EP2146991A2 Triazolopyridine carboxamide derivatives, preparation thereof and therapeutic use thereof |
| 01/27/2010 | EP2146988A1 New 4,8-diphenyl-polyazanaphthalene derivatives |
| 01/27/2010 | EP2146985A1 Heterocyclic compounds and their methods of use |
| 01/27/2010 | EP2146980A2 Histamine h3 receptor ligands comprising a cyclobutoxy group |
| 01/27/2010 | EP2146979A1 A new process for the manufacturing of the compound 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]1h-indole-5-carbonitrile 701 |
| 01/27/2010 | EP2146968A1 Urea derivatives as glutaminyl cyclase inhibitors |
| 01/27/2010 | EP2146962A2 Novel vanilloid receptor ligands and the use thereof for the production of pharmaceuticals |
| 01/27/2010 | EP2146961A1 N-oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles |
| 01/27/2010 | EP2146946A2 Stereoisomeric propofol therapeutic compounds |
| 01/27/2010 | EP2146746A2 Prevention and treatment of cerebral amyloid angiopathy |
| 01/27/2010 | EP2146739A2 Methods of immune or hematological enhancement, inhibiting tumour formation or growth, and treating or preventing cancer, cancer symptoms, or the symptoms of cancer treatments |
| 01/27/2010 | EP2146731A1 New use for cannabinoid-containing plant extracts |
| 01/27/2010 | EP2146726A1 Dihydropyridine derivative for treating cancer or a pre-cancerous condition and other conditions |
| 01/27/2010 | EP2146725A1 A composition for regulating cellular senescence comprising n-[2-(cyclohexyloxyl)-4-nitrophenyl]-methanesulfonamide |
| 01/27/2010 | EP2146723A1 Means and methods for counteracting protein aggregation |
| 01/27/2010 | EP2146722A1 Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
| 01/27/2010 | EP2146714A1 Use of 4-cyclopropylmethoxy-<i>n</i>-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of motor disorders related to parkinson's disease |
| 01/27/2010 | EP2146713A2 Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of cranial traumas |
| 01/27/2010 | EP2146712A1 Aryl heterocyclic cgrp receptor antagonists |
| 01/27/2010 | EP2146576A1 Treatment of down syndrome with benzodiazepine receptor antagonists |
| 01/27/2010 | EP2146572A1 Bicyclic anilide heterocyclic cgrp receptor antagonists |
| 01/27/2010 | EP1830833B1 Combination of a glycine transporter (glyt1) inhibitor and an antipsychotic for the treatment of symptoms of schizophrenia as well as its preparation and use thereof |
| 01/27/2010 | EP1656353B1 Gabanergic modulators |
| 01/27/2010 | EP1554286B1 Fused heterocyclic isoxazoline derivatives and their use as anti-depressants |
| 01/27/2010 | CN101632676A Triazinone compounds for treating diseases resulting from infestation with parasitic protozoans |
| 01/27/2010 | CN101632663A Novel molecular target for neurotoxicity |
| 01/27/2010 | CN100584945C Nuclear-envelope and nuclear-lamina binding chimeras for modulating gene expression |
| 01/27/2010 | CN100584851C Phosphates of secondary alcohols |
| 01/27/2010 | CN100584830C Gabanergic modulators |
| 01/27/2010 | CN100584819C Substituted 4-aminocyclohexanol derivatives |
| 01/27/2010 | CN100584807C Deuterated catecholamine derivatives and medicaments comprising said compounds |
| 01/27/2010 | CN100584383C Pharmaceutical composition with Meclofenoxate hydrochloride capable of preventing hydrolysis |
| 01/27/2010 | CN100584379C Botulinum toxin treatments of neurological and neuropsychiatric disorders |
| 01/27/2010 | CN100584373C Preparation process of medicine for treating cerebral apoplexy and its sequela |
| 01/27/2010 | CN100584364C A blood circulation-invigorating tendon-strengthening capsule and preparation process thereof |
| 01/27/2010 | CN100584354C A medicine for treating zoster sequela neuralgia |
| 01/27/2010 | CN100584343C Medicine health-care usage of globefish I collagen extraction and preparing process thereof |
| 01/27/2010 | CN100584322C Compositions comprising modafinil compounds |
| 01/27/2010 | CN100584319C Multiple apertures releasing osmosis pump control release tablet and preparation process thereof |
| 01/27/2010 | CN100584219C Alcohol-decomposing beverage |
| 01/27/2010 | CN100584207C Agastache mate tea |
| 01/26/2010 | US7652155 Diamine derivative, production process therefor and antioxidant |
| 01/26/2010 | US7652144 Compounds as PDE IV and TNF inhibitors |
| 01/26/2010 | US7652141 Immunosuppressants, analgesics, antiinflammatory agents |